U.S.-listed shares of Sanofi (SAN.FR) gained 0.4% in trading on Friday after it announced that co-administering a flu shot with Moderna Inc.'s (MRNA) experimental COVID-19 booster in seniors is safe and effective. Moderna's stock was down 2.7%. The interim findings came from a study of about 300 participants, and they showed a similar immune response and safety signal when giving the shots at the same time compared with giving the shots separately. Sanofi's flu shot, Fluzone High-Dose Quadrivalent, is approved in the U.S. for people who are 65 years old and older. Moderna's booster candidate is currently under review for emergency authorization at the Food and Drug Administration. So far this year, Sanofi's stock has gained 0.5% and Moderna shares have soared 187.8%, while the broader S&P 500 is up 16.1%.
(END) Dow Jones Newswires
October 08, 2021 10:38 ET (14:38 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.